Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSM01 Safety and PK in Healthy Adults
NCT05118386Phase 1Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSM01 Experimental Arm with Placebo Comparator Arm (2 arms). Primary endpoints: Number of Participants With Unsolicited Treatment Emergent Adverse Events Through Day 151, Number of Participants With Serious Adverse Events and AE of Special Interest Through Day 151 and 2 more. Started Nov 2021; status: completed.
02
Drugs
RSM01
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05118386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118386.